Target Acquisition ProtaTek International was acquired by Pharmgate LLC in 2016, presenting an opportunity for complementary bio-products or vaccine partnerships within the swine industry and related biotech sectors.

Growth Potential With recent revenue estimates between 1M and 10M and a focused niche in vaccine development, ProtaTek offers prospects for expanding pharmaceutical or biotech product lines tailored to animal health markets.

Technology Stack Utilizing advanced platforms like Microsoft Azure and open-source tools such as WordPress and MySQL, the company may be open to collaborations in cloud-based biotech applications and digital data management solutions.

Market Segment Specialized in swine vaccines, ProtaTek operates within the competitive animal health and biotech space, aligned with larger players serving global markets, which suggests avenues for strategic alliances or distribution channels.

Innovation Opportunities Given their biotech research focus and recent ownership change, there is potential for introducing innovative vaccine technologies or research partnerships to accelerate product development and market entry.